Literature DB >> 6714292

Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.

M Eichelbaum, A Somogyi.   

Abstract

The pharmacokinetics of verapamil in five healthy volunteers were investigated on 4 occasions during chronic administration of deuterated verapamil. There was no statistically significant difference in oral clearance, terminal half-life, bioavailability, morning trough level and peak concentration or in the time of their occurrence on the four occasions. The plasma clearance, however, exhibited considerable inter- and intra-individual variation, ranging between 26.3% and 85.4% and 12.0% and 48.0%, respectively. Comparison of these pharmacokinetic parameters with data from previous single dose studies in the same subjects revealed a significant (p less than 0.05) decrease in the clearance and an increase in the apparent bioavailability of verapamil during chronic administration, although no difference in the half-life was found. Due to the considerable variation in the oral clearance of verapamil during chronic dosing, steady-state conditions in a strict pharmacokinetic sense may never be attained, and pharmacokinetic data obtained in single dose studies will be of limited value in predicting steady-state plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6714292     DOI: 10.1007/bf00546708

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  34 in total

1.  Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors:  A Melander; K Danielson; B Scherstén; E Wåhlin
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

Review 2.  Drug use in the elderly: a review of problems and special considerations.

Authors:  R E Vestal
Journal:  Drugs       Date:  1978-10       Impact factor: 9.546

3.  Influence of the route of administration on the area under the plasma concentration-time curve.

Authors:  P A Harris; S Riegelman
Journal:  J Pharm Sci       Date:  1969-01       Impact factor: 3.534

4.  Variability of beta-blocker pharmacokinetics in young volunteers.

Authors:  D B Jack; C P Quarterman; R Zaman; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data.

Authors:  A Somogyi; M Eichelbaum; R Gugler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Prolongation of verapamil elimination kinetics during chronic oral administration.

Authors:  J B Schwartz; D L Keefe; E Kirsten; R E Kates; D C Harrison
Journal:  Am Heart J       Date:  1982-08       Impact factor: 4.749

Review 7.  Drug pharmacokinetics in cardiac and hepatic disease.

Authors:  R L Williams; L Z Benet
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

8.  Simultaneous determination of verapamil and its seven metabolites by high-performance liquid chromatography.

Authors:  M Kuwada; T Tateyama; J Tsutsumi
Journal:  J Chromatogr       Date:  1981-03-13

9.  Physiological disposition of verapamil in man.

Authors:  M Schomerus; B Spiegelhalder; B Stieren; M Eichelbaum
Journal:  Cardiovasc Res       Date:  1976-09       Impact factor: 10.787

10.  Verapamil kinetics in normal subjects and patients with coronary artery spasm.

Authors:  S B Freedman; D R Richmond; J J Ashley; D T Kelly
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

View more
  21 in total

1.  Dissolution and in vivo evidence of differences in reference products: impact on development of generic drugs.

Authors:  M Spino; Y C Tsang; R Pop
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

2.  Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers.

Authors:  D N John; S Fort; M J Lewis; D K Luscombe
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

3.  Stepwise determination of multicompartment disposition and absorption parameters from extravascular concentration-time data. Application to mesoridazine, flurbiprofen, flunarizine, labetalol, and diazepam.

Authors:  J G Wagner; D A Ganes; K K Midha; I Gonzalez-Younes; J C Sackellares; L D Olson; M B Affrime; J E Patrick
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

Review 4.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 5.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

6.  Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects.

Authors:  Julia Hanna; David J R Foster; Amy Salter; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

7.  Pharmacokinetic interaction between verapamil and everolimus in healthy subjects.

Authors:  J M Kovarik; D Beyer; M N Bizot; Q Jiang; M J Allison; R L Schmouder
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

8.  Pharmacokinetics and pharmacodynamics of two formulations of verapamil.

Authors:  K K Hla; J A Henry; A N Latham
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

9.  The effect of oral verapamil therapy on antipyrine clearance.

Authors:  D O Rumiantsev; V K Piotrovskii; O S Riabokon; I D Slastnikova; E V Kokurina; V I Metelitsa
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

Review 10.  Influence of diet and nutritional status on drug metabolism.

Authors:  I Walter-Sack; U Klotz
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.